首页> 外文期刊>P & T: a peer-reviewed journal for formulary management >Brexpiprazole (Rexulti) A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder
【24h】

Brexpiprazole (Rexulti) A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder

机译:Brexpiprazole(Rexulti)精神分裂症的新单一疗法及重度抑郁症的辅助疗法

获取原文
获取原文并翻译 | 示例
           

摘要

Mental health disorders affect approximately one in five adults in a given year. In the United States, approximately 1% of adults live with schizophrenia, and nearly 7% of adults have experienced at least one major depressive episode.The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), defines schizophrenia as having two or more of the following symptoms for a substantial amount of time during a one-month period that leads to a significant decrease in level of functioning. The symptoms include grossly disorganized or catatonic behavior, negative symptoms (i.e., avolition or reduced emotional expression), and at least one of these symptoms: delusions, hallucinations, or disorganized speech.
机译:在给定的一年中,心理健康障碍会影响大约五分之一的成年人。在美国,约1%的成年人患有精神分裂症,并且近7%的成年人经历过至少一次严重的抑郁发作。《精神障碍诊断和统计手册》第五版(DSM-5)将精神分裂症定义为患有在一个月的时间内,以下两种或多种以下症状会持续大量时间,从而导致功能水平显着下降。症状包括严重失调或紧张的行为,消极症状(即过失或情绪低落)和以下症状中的至少一种:妄想,幻觉或言语混乱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号